Tonix to Discuss Fibromyalgia Study Results at BIO CEO & Investor Meet

Tonix to Discuss Fibromyalgia Study Results at BIO CEO & Investor Meet
Tonix Pharmaceuticals Holding Corp., a company developing next-generation therapeutics for fibromyalgia, episodic tension-type headaches, and post-traumatic stress disorder (PTSD), is among the participants at the  18th annual BIO CEO & Investor Conference. At the Feb. 8 conference in New York City, Tonix’s president and CEO, Seth Lederman, MD, is providing an overview of clinical studies into its fibromyalgia and other treatments, due to be reported later in 2016, as well as a corporate update. An ongoing Phase 3 registration study is investigating TNX-102-SL, a sublingual formulation of cyclobenzaprine HCL 2.8 mg, designed to be taken at bedtime to ensure a restful sleep. The medication's safety and efficacy have already been demonstrated in an earlier trial. Results from the randomized, double-blind, placebo-controlled AFFIRM trial are expected in the third quarter of 2016. TNX-102-SL intends to help treat fibromyalgia symptoms by improving sleep quality. Around 90 percent of patients suffer from sleep deprivation, and evidence suggests that improving their ability to rest could be a successful therapeutic strategy. Another drug in clinical testing, TNX-201, aims to treatment episodic tension-type headaches without barbiturates, a common medication prescribed for this condition. TNX-201 is among a new class of
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *